Eur Rev Med Pharmacol Sci 2023; 27 (6): 2543-2551
DOI: 10.26355/eurrev_202303_31788

Galectin-1 as a potential diagnostic biomarker in polycystic ovary syndrome

H. Aladag, T.R. Kiran, F. İnceoglu, E. Yildirim, B. Yaprak, A.B. Karabulut, M. Aladag

Department of Obstetrics and Gynecology, Department of Biochemistry, Department of Biostatistics, Faculty of Medicine, Malatya Turgut Özal University, Malatya, Turkey. murataladag@hotmail.com


OBJECTIVE: This study was aimed at comparing the routine laboratory parameters and Galectin-1 levels of control and polycystic ovarian syndrome patients.

PATIENTS AND METHODS: 88 patients diagnosed with polycystic ovary syndrome and 88 healthy controls were considered for the study. Age groups of the patients ranged from 18 to 40. Serum TSH, Beta HCG, glucose, insulin, HOMA-IR, Hb1A1c, triglyceride, total cholesterol, LDL FSH, LH, E2, prolactin, testosterone, SHBG, DHESO4, HDL, Gal-1 levels were analyzed for each subject.

RESULTS: FSH, LH, LH/FSH, E2, prolactin, testosterone, SHBG, DHESO4, HDL and Gal-1 values of the subjects included in the study were statistically significantly different between the groups (p<0.05). Gal-1 and DHESO4 showed a strong positive connection (p=0.05). The sensitivity of Gal-1 level in PCOS patients was calculated as 0.997 and specificity as 0.716.

CONCLUSIONS: High levels of Gal-1 in PCOS patients suggest that it increases due to overexpression in response to inflammation.

Free PDF Download

To cite this article

H. Aladag, T.R. Kiran, F. İnceoglu, E. Yildirim, B. Yaprak, A.B. Karabulut, M. Aladag
Galectin-1 as a potential diagnostic biomarker in polycystic ovary syndrome

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 6
Pages: 2543-2551
DOI: 10.26355/eurrev_202303_31788